![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 23287-23294, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
§,
,
¶,
,
**,
, and
§§
From the
British Columbia Cancer Research Centre,
British Columbia Cancer Agency, University of British Columbia,
Vancouver, V5Z 1L3 Canada and the

Department of Pathology, Vancouver General
Hospital, University of British Columbia, Vancouver, V5Z 1M9 Canada
Received for publication, March 5, 2000
| |
ABSTRACT |
|---|
|
|
|---|
We have cloned full-length human and mouse
cDNAs of ABCB9, which encodes a predicted multiple-spanning
transmembrane domain and a nucleotide-binding domain with Walker
motifs. It is therefore designated as a "half" ATP binding cassette
(ABC) transporter. Northern analysis shows that the ABCB9 mRNA is
expressed at a high level in testes and moderate levels in brain and
spinal cord. A splice variant mRNA deleted in the last pair of
predicted transmembrane segments was shown to be expressed in human
tissues. Phylogenetic analysis indicates that ABCB9 is closely related
to TAP1 and TAP2, two "half" ABC proteins found in endoplasmic
reticulum. ABCB9 protein colocalized with the lysosomal markers, LAMP1
and LAMP2, in transfected cells. ABCB9 protein appears to be most
highly expressed in the Sertoli cells of the seminiferous tubules in mouse and rat testes. These cells have high levels of phagocytosis and
secretory activities. These findings pave the way for further investigation into the potential novel function of ABCB9 in lysosomes.
The ATP binding cassette
(ABC)1 transporter
superfamily is one of the largest gene families found in both
eukaryotic and prokaryotic cells. ABC proteins contain a multispanning
transmembrane domain(s) and a highly conserved nucleotide binding
domain(s) (NBD) (1). In eukaryotic cells, ABC transporters participate
in the translocation of a variety of molecules across cellular
membranes or intracellular organelle membranes. These tasks are divided
between full transporters, which consist of two transmembrane domain(s)
and two NBDs, and half transporters, which contain one of each domain.
In mammalian cells, full transporters are usually found in plasma
membranes, which include the multiple drug transporters, P-glycoprotein
(2) and MRP (3), and the chloride channel CFTR (4). Conversely, all
half transporters characterized to date are found in subcellular organelles. Half transporters are likely to function either as homodimers or heterodimers. The best-studied examples are TAP1 and
TAP2, which form a heteromeric complex for translocating antigenic peptides from the cytoplasm to the lumen of the endoplasmic reticulum (ER) to bind major histocompatibility complex class I molecules (5, 6).
Four half transporters (PMP70, ALDP, PMP69, and ALDR) have been found
in peroxisomal membranes (7-10). PMP70 and ALDP are linked to the
genetic diseases Zellweger syndrome (associated with a peroxisome
biogenesis disorder) and adrenoleukodystrophy (associated with an
oxidation of very long chain fatty acids defect) (11, 8). In
mitochondria, two half transporters (M-ABC1, ABC7) have been identified
(12, 13). Mutations in the human ABC7 gene are associated with X-linked
sideroblastic anemia and ataxia (14).
No ABC transporter has been reported to be localized in mammalian
lysosomal membranes; however, an ABC protein, HMT1, has been found in
the fission yeast vacuolar membrane, the lysosomal compartment of
yeast. It is involved in heavy metal tolerance (15). Mammalian
lysosomes are responsible for the breakdown of cellular components and
also serve as a sink for toxins, drugs, and heavy metals. Lysosomes are
required to take up a variety of substances from the cytosol and
release recycled precursors to the cytosol for macromolecule synthesis.
Therefore, transport activities moving a wide range of molecules across
lysosomal membranes must occur. Indeed, a number of lysosomal transport
processes have been shown to be ATP-dependent, but
transporters have not yet been identified. Among these events are
translocation of peptides to lysosomes along the pathway for selective
degradation of cytosolic proteins under nutritionally depleted
conditions (16), heavy metal ion translocation to lysosomes for heavy
metal metabolism (17), and free oligosaccharide translocation (18). ABC
proteins, known to transport a wide range of molecules from ions to
proteins, are potential candidates for any one of these transport activities.
In this report, we describe a novel mammalian ABC transporter that is
localized to the lysosomes in transfected cells. We have cloned this
gene from both human and mouse, and designated them hABCB9 and mABCB9,
respectively (Human ABC gene nomenclature committee). The similarity of
ABCB9 to the TAP proteins has recently been noted by Yamaguchi et
al. (19) when the rat ortholog of ABCB9, TAPL, was isolated. The
lysosomal location of the ABCB9 protein has been demonstrated in cells
transfected with a full-length hABCB9 cDNA by both
immunofluorescence and subcellular fractionation. The ABCB9 protein
expression has been examined in mouse and rat testis, because ABCB9
mRNA is most highly expressed in this tissue. Using ABCB9-specific
antiserum, ABCB9 is located to the cytoplasmic compartment of Sertoli
cells in the seminiferous epithelium. These cells play multiple
functions in nurturing and supporting germ cells, and they possess
numerous lysosomes for phagocytosis.
Construction of cDNA Libraries--
Poly(A)+ RNA
from adult brain of C57BL/6J mouse was isolated by using Trizol Reagent
and oligo(dT) cellulose columns (Life Technologies, Inc.). Double
stranded cDNAs were synthesized with oligo(dT) primer (SuperScript
II; Life Technologies, Inc.) and ligated to Lambda Zap II (Stratagene).
The Lambda ZapII/cDNA was packaged into bacteriophage particles
using the Gigapack III Gold-packaging extract (Stratagene).
Cloning of ABCB9 cDNAs--
The cDNA insert of EST clone
c-1ch05 (Program Genexpress, Laboratorie Genethon, Evry, France)
(GenBankTM accession number F06569) was used as a probe to screen a
human acute lymphoblastic leukemia CCRF-CEM cDNA library (12). Two
cDNA clones, c1-l and c1-s, were isolated. Manual sequencing was
performed using the dideoxynucleotide chain termination method (U.S.
Biochemicals). An additional 44 nucleotides from the 5'-end were
obtained using 5'-RACE of poly(A)+ RNA from the CEM cell
line using the Marathon cDNA Amplification Kit
(CLONTECH) and the ABCB9-specific primers E1-12b
(5'-GGATGGGCCTGCGCACCTCT) and E1-7b (5'-CACTCATGAAGGCCAAAG). The
polymerase chain reaction (PCR) products were cloned into pCR2.1 (Invitrogen).
For cloning the mouse ABCB9 cDNA, A 1.3-kilobase (kb)
fragment of hABCB9 cDNA (nucleotides (nt) 2152-3512)
was used as a probe to screen the mouse brain cDNA library with low
stringent hybridization condition. The longest cDNA clone, m1-9,
was sequenced by BigDye Terminator Cycle Sequencing Ready Reaction
using a Model 310 DNA Sequencer (Applied Biosystems).
DNA sequence was analyzed using GCG program software (Genetics Computer
Inc.) and protein analysis using the TopPredII program (20). The
nucleotide sequences for the hABCB9 and mABCB9 cDNAs have been
deposited in the GenBankTM data base under accession numbers AF216494
and AF216495, respectively.
Phylogenetic analysis was performed by aligning amino acid sequences of
hABCB9 and mABCB9 along with representative ABC transporters using
ClustalX (21). A neighbor-joining bootstrap tree was generated from the
alignment using PAUP*4.0 (22). The GenBankTM accession numbers for the
ABC proteins employed were: TAP1, X57522; MDR1, 4505769; M-ABC1,
AF047690; M-ABC2, AF216833; TAPL, AB027520; TAP2, M74447; ABC7,
AB005289; UMAT, AJ003004; MDL1, U17246; MDL2, L16959; ATM1, Z49212; and
HMT1, AL031546.
Northern Analysis and Reverse Transcription-PCR--
A
32P-labeled 1.3-kb fragment of hABCB9 cDNA
(nt 2152-3512) was hybridized to human multiple tissue Northern blots
(CLONTECH). A 1.2-kb fragment of mABCB9
cDNA (nt 258-1513) was used for hybridization to multiple mouse
tissue Northern blot (20 µg of total RNA from designated tissue). The
same blot was hybridized to a control probe (a fragment of actin cDNA).
The first strand cDNA was randomly primed by using 1 µg of total
RNA of designated tissues in 40 µl of reverse transcription (RT)
reaction. Different aliquots of RT reaction (as indicated below in Fig.
3C) were amplified by PCR with primers E1-13A
(5'-TGGTGTCCAACATCTACGGC), and E1-8B (5'-TCCCTGCATCAGGCCACT) under the
cycling procedure: 94 °C for 1 min, then 40 cycles consisting of
94 °C for 10 s, 55 °C for 10 s, and 72 °C for 20 s.
Transfection--
The EcoRI fragment of c1-l
cDNA, containing the entire coding sequence of ABCB9,
was subcloned into the pCDNA3 (Invitrogen) and transfected into the
human ovarian SKOV3 cell with Lipofectamine (Life Technologies, Inc.).
Stably transfected cells (SKOV/ABCB9) were selected with 800 ng/ml
Geneticin and maintained with 400 ng/ml Geneticin (Life Technologies,
Inc.) in growth medium.
Antibodies--
For the bacteria expression vector encoding a
glutathione S-transferase (GST) fusion protein with the
C-terminal 36 amino acids of the human ABCB9 protein (GST/ABC), a pair
of primers (5'-TACGGGATCCGGCGGCCTCTACGCCAA-3',
BamHI site underlined and 5'-TACGGAATTCAGGCCTTGTGACTGCC-3', EcoRI site
underlined) was used for PCR amplification of the hABCB9
gene. The PCR fragment was digested with EcoRI and
BamHI and cloned into the pGEX2T vector to generate pGEX-1C.
The GST/ABC fusion protein was expressed in DH5
Immunoaffinity purification of the anti-ABCB9 serum was carried out
using the methods from Ref .35. The MalE fusion protein containing the
C-terminal 36 amino acids of hABCB9 was linked directly to
CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech) for the
preparation of an antigen column.
ABCB9 "positive" and "negative" sera were prepared by adsorbing
the anti-ABCB9 serum overnight with either the GST or the GST/ABC
protein immobilized on Immobilon-P transfer membranes (Millipore), respectively.
Monoclonal antibodies to GPP130 (A1/118) (25) and transferrin receptor
(G1/122) were generous gift form Dr. H. P. Hauri (University of
Basel, Switzerland). Polyclonal antiserum to alcohol dehydrogenase was
kindly provided by Dr. H. Weiner (Purdue University, West LaFayette,
IN). The following antibodies are purchased: monoclonal antibodies to
LAMP1 (H4A3) and LAMP2 (H4B4) (Developmental Studies Hybridoma Bank,
University of Iowa, Iowa City), monoclonal antibody to Calnexin (AF18;
Stressgen), donkey anti-rabbit IgG conjugated to fluorescein
isothiocyanate (FITC), donkey anti-mouse IgG conjugated to lissamine
rhodamine (LRSC), and goat anti-rabbit IgG conjugated to biotin
(Jackson ImmunoResearch).
Immunofluorescence--
SKOV3 cells were grown on glass slides
to 50% confluence, fixed with 3% paraformaldehyde in
phosphate-buffered saline (PBS) with 5 mM CaCl2
and 10 mM MgCl2 (PBS-MC) for 20 min, and wash with (PBS-MC) three times. The cells were made permeable with 0.1%
saponin in PBS-MC with 3% bovine serum albumin (BSA) for 10 min.
Primary antibodies were applied in PBS-MC with 3% BSA and 0.1%
saponin and incubated at 37 °C for 40 min. After three washes
(PBS-MC-0.1% saponin), cells were incubated at 37 °C for 40 min
with secondary antibodies (LRSC-conjugated anti-mouse IgG and
FITC-conjugated anti-rabbit IgG) in PBS-MC-3% BSA-0.1% saponin. Cells
were rinsed twice with PBS-MC-0.1% saponin, rinsed twice with PBS-MC,
and then mounted with fluorescent mounting medium (Dako, Carpinteria,
CA). The specimens were examined with a Zeiss fluorescence microscope.
Immunohistochemistry--
Frozen sections of mouse and rat
testis were fixed in acetone and stained with the positive or negative
serum by using an avidin-biotin-peroxidase complex technique. The
sections were incubated sequentially with 3%
H2O2:methanol (1:1, v/v) for 30 min, 10%
normal goat serum in TBS-T (50 mM Tris, pH 7.6, 150 mM NaCl, 0.05% Tween) for 30 min, primary antibody in
TBS-T with 1% BSA for 60 min, biotin-conjugated anti-rabbit IgG in
TBS-T with 1% BSA for 60 min, and streptavidin-conjugated horseradish peroxidase (Jackson ImmunoResearch) in TBS-T with 1% BSA for 70 min.
The binding of antibody to tissues was detected by 6-min incubation
with 3-amino-9-ethylcarbazole (Sigma) and H2O2
(0.00015%). Tissues were counterstained with hematoxylin and mounted
in Crystal/Mount (Biomeda Corp.)
Membrane Preparations--
All procedures were performed at
4 °C. Total membranes from cultured cells were prepared by
resuspending cell pellets in ST buffer (250 mM sucrose, 5 mM Tris, pH 8, 2 mM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, and 1%
aprotinin). Suspended cells were Dounce-homogenized (30 strokes) with B
pestle and then centrifuged at 4500 × g for 10 min to
remove nuclei and unbroken cells. Total membrane fractions were
collected by centrifugation at 100,000 × g (60 min).
The metrizamide (Mz) (Accurate Chemical Co.) step gradients were
performed according to the method by Storrie and Madden (26) with
modifications. Briefly, monolayer cells (108) were
harvested according to the manufacturer's instructions (Application
Sheet 3.2: "homogenization of mammalian cultured cells"; Nycomed
Pharma Co., Life Technologies, Inc.). Cell suspensions were
Dounce-homogenized for 15 strokes with B pestle and centrifuged at
1300 × g for 10 min. Supernatants (PNS or Fraction I)
were overlaid on top of the first gradient (6% Percoll (Amersham
Pharmacia Biotech)/17% Mz/35% Mz) and centrifuged at 50,500 × g for 40 min. Bands at the PNS/6% Percoll interface
(Fraction II), the 6% Percoll/17% Mz interface (Fraction III), and
the 17% Mz/35% Mz interface (Fraction IV) were collected. Fraction
III was then mixed with Mz to 35% and then applied to the bottom of
the layer gradient (5% Mz/17% Mz/35% Mz). After centrifugation at
50,500 × g (40 min), bands at the 5% Mz/17% Mz
interface (Fraction V) and the 17% Mz/35% Mz interface (Fraction VI)
were collected. Protein concentration of each fraction was determined
by protein assay (Bio-Rad).
Percoll Gradient--
275 µl of Fraction V was mixed with 11 ml of 19.25% Percoll in 250 mM sucrose, 10 mM
Hepes, pH 7.4, and 0.2 mM EDTA (final Percoll 18.8%),
layered on top of a 1-ml cushion of 2.5 M sucrose, and
centrifuged in a Type 65 rotor for 60 min at 28,000 × g. 0.5-ml fractions were collected from the bottom of the
gradient. Proteins separated by SDS-polyacrylamide gel electrophoresis
(PAGE) were transferred to an Immobilon-P membrane (Millipore), and
Western analysis was visualized with ECL reagent (Amersham Pharmacia Biotech).
Characterization of the ABCB9 cDNA--
We initially
identified the EST clone c-1ch05 (GenBankTM accession number F06569) as
a human ABC gene (ABCB9) by using the BLASTN program (27) to search the
dbEST data base with the conserved NBDs of the known ABC transporters
as query sequences. This gene was of interest, because it exhibited a
restricted high expression pattern to testis and brain by Northern blot
analysis. An EST clone corresponding to the same gene was mapped to
chromosome 12q24 by Allikmets et al. (28) as part of an
investigation to classify 33 human ABC transporters; however, no
further characterization of this gene was undertaken. To study the
function of ABCB9, we proceeded to clone a full-length cDNA of this
gene. Using the cDNA insert of the EST clone c-1ch05 as a probe to
screen a human T-lymphoblast CEM cell line cDNA library, we
isolated two independent cDNA clones, c1-l and c1-s. Clone c1-l
consists of 3468 base pairs (bp), and an additional 44 nucleotides at
the 5'-end were obtained by 5'-RACE. The full-length cDNA of hABCB9
is thus 3512 bp consisting of 298 bp of a 5'-untranslated region, an
open reading frame of 2298 bp coding for 766 amino acids, and 916 bp of
a 3'-untranslated region. As shown in Fig.
1A, the predicted protein
sequence reveals that hABCB9 contains structural motifs of a half ABC
transporter with a single NBD in its C-terminal region. Hydropathy
analysis using the Eisenberg algorithm of the TopPredII program (20) suggests the presence of 10 potential transmembrane segments in the
N-terminal portion of the molecule.
A 3325-bp cDNA clone of the mouse homologue of hABCB9 (mABCB9)
encoding a 762-amino acid protein was also isolated from a mouse brain
cDNA library. Fig. 1A shows an amino acid sequence alignment of the human, mouse, and rat (TAPL) ABCB9 genes. The similarity between mouse and rat sequences is 99% of the amino acid
identity (Table I). The percentage of
amino acid identity between human and rodent is 94%, with the major
differences clustered in the predicted cytoplasmic domain between the
transmembrane segment 4 (TM 4) and TM 5, and the C-terminal end.
Phylogenetic analysis of ABCB9 with known ABC transporter proteins was
performed using the alignment program ClustalX (21) and the
tree-generating program PAUP*4.0 (22). A neighbor-joining analysis
showed that ABCB9 falls into the same cluster as the P-glycoprotein and
TAP proteins. Within this cluster, ABCB9 appeared to be closely related
to TAP1 and TAP2, which are two ABC proteins found in ER (Fig.
2). Alignment of the three proteins using
the GAP program (Wisconsin GCG package) indicated an identity of hABCB9 to TAP 1 and TAP2 of 38% and 40%, respectively (Table I). The identity between the two TAP proteins was 39%.
Identification of a Splice Variant of hABCB9--
A shorter
cDNA clone of hABCB9 (c1-s) was isolated that had the same sequence
as c1-l, except for four internal deletions of 2 bp (from nt 1350 to
1351 and from nt 1902 to 1903), 14 bp (nt1015-1028), and 129 bp
(nt1550-1688). Among those, only the 129-bp deletion is in-frame. To
determine whether these "deletions" were present in native mRNA
or were cloning artifacts, we performed RT-PCR amplification of RNA
from CEM cells, the same cell line from which the cDNA clone was
isolated. A series of primers were chosen such that each PCR product
would include the 129-bp deletion and one or two of the small deletions
in c1-s cDNA. Two bands corresponding to c1-s and c1-l were
detected from all PCR reactions. The c1-s bands were subcloned for
sequence analysis, which showed that the 129-bp, in-frame deletion was
found among all PCR clones examined, whereas none of the three small
frameshift deletions were found. We concluded that the three frameshift
deletions seen in c1-s were cloning artifacts, whereas the 129-bp
deletion exists as an isoform of hABCB9 mRNA.
Southern blot analysis of genomic DNA indicates that there is only one
copy of the hABCB9 gene in the human genome (data not shown);
therefore, these two forms of mRNA are likely to be derived by
alternative splicing. It is known that intron/exon boundaries are often
conserved among closely related members in a gene family. Because the
genomic structure of the hABCB9 locus is unknown, we checked the
genomic arrangement of the two half ABC transporters, TAP1 and TAP2
(NCBI accession numbers X66401 and S57528). Fig. 1B displays
a portion of the aligned amino acid sequence of these three proteins
and indicates that the 129-bp deletion in hABCB9 corresponds to exon 6 of both TAP1 and TAP2. This finding strongly suggests that the short
form of hABCB9 mRNA is a splice variant that has skipped
one exon. This presumptive 129-bp exon encodes 43 amino acids
encompassing the last hydrophobic region (predicted TM9 and TM10)
before the ATP binding domain (see Fig. 1A). This region
corresponds to TMs of P-glycoprotein that are involved in drug binding
(29). The splice variant protein may be speculated to have a substrate
specificity different from that of the regular hABCB9.
We further examined the existence of this mRNA splice variant in
normal tissues by RT-PCR amplification of RNA from human testis and
brain, because hABCB9 is expressed relatively highly in
these two tissues (Fig. 3A). A
pair of primers, flanking the 129-bp deletion region in c1-s, is
expected to generate RT-PCR products of 266 and 395 bp from mRNAs
corresponding to the cDNA clones c1-s and c1-l, respectively.
RT-PCR products from testis and brain showed two bands of the expected
sizes, with the c1-l band being more prominent (Fig. 3C).
The c1-s band appears to be less abundant in testis than in brain.
These data indicate that the c1-l and c1-s forms of hABCB9 mRNA are
coexpressed in both human brain and testis. However, the ratio of these
two forms are different.
Northern Blot Analysis of ABCB9 mRNA Expression--
The
expression patterns of ABCB9 in a panel of normal adult human tissues
was investigated by Northern blot analysis. As shown in Fig.
3A, most tissues examined appeared to express low levels of
hABCB9, however, relatively high expression was found in the testis,
and moderate expression was found in brain, spinal cord, and thyroid.
In addition to the expected band (about 3.7 kb), an additional 2.2-kb
band was also detected in the tissues in which hABCB9 are highly
expressed. The probe used for this Northern blot contains a 1.3-kb
hABCB9 sequence at the 3'-end; therefore, the 2.2-kb band likely
presents a specific degradation product or another splice variant.
ABCB9 mRNA expression patterns in mouse tissues were
similar to human: high expression was found in mouse testis, and
moderate expression was found in brain and in spinal cord. It should be noted that, unlike the human blot where poly(A)+ RNA was
used, total RNA was used in the mouse blot (Fig. 3B). Therefore, it is possible that a lower level of expression of mABCB9 in
other mouse tissues may not be detected due to the relative insensitivity of the assay.
ABCB9 Protein Expression and Drug Resistance in Transfected
Cells--
To facilitate the study of potential ABCB9 functions,
hABCB9 cDNA was subcloned into an expression vector and stably
transfected into a human ovarian carcinoma cell line SKOV3. The
expression of hABCB9 in transfected cells (SKOV/ABCB9) was examined by
Western blot using polyclonal antiserum against a GST fusion protein
containing the C-terminal 36 amino acids of hABCB9. A prominent band of
approximately 72 kDa was detected using the ABCB9-specific antibody
(Fig. 4A, lanes 2 and 3), which is significantly smaller than the predicted molecular mass of hABCB9 (84.5 kDa). A similar discrepancy has also
been reported previously in the E. coli half ABC
transporter hemolysin B, a protein with a 79.9-kDa predicted molecular
mass but 66 kDa as measured by SDS-PAGE (30). These differences may be
due to either the aberrant behavior of highly hydrophobic proteins on
SDS gels or post-translational modification.
Using antisera preadsorbed with either GST-ABCB9 fusion protein
(GST/ABC) or GST alone, an identical experiment was performed to
confirm the specificity of the antibody. Treatment with GST/ABC but not
with GST alone abolished the detection of the 72-kDa band (Fig.
4A). A faint band of approximately 72 kDa was also observed in the control cells, but that band was not abolished with
GST/ABC-treated antiserum and therefore was not hABCB9.
Five N-glycosylation sequence motifs were found in ABCB9
protein (Fig. 1A). To determine whether hABCB9 contained
N-linked oligosaccharides, a membrane preparation was
digested with N-glycosidase F prior to Western blot
analysis. This treatment did not change the mobility of the detected
band, indicating that hABCB9 was not N-glycosylated
(Fig. 4B). If the predicted topological structure of ABCB9
is such that the NBD is in the cytoplasmic compartment, then all the
N-glycosylation site would be in the predicted cytoplasmic loops and unlikely to be used. Our results appear to confirm this prediction.
It is not known whether ABCB9 is able to function alone as a homodimer
or needs to form a complex with another half ABC transporter. It has
been demonstrated recently that transfection of a half ABC transporter,
BCRP, alone was able to render cells resistant to a number of drugs
(31). To determine whether ABCB9 overexpression may give rise to drug
resistance, an hABCB9 high expression clone, an intermediate expression
clone, and the control cells (vector-transfected cells) were exposed to
the compounds colchicine, vinblastine, taxol, actinomycin D, etoposide,
methotrexate, daunorubicin, and cisplatin. No difference in drug
sensitivity was observed between transfected cells and control cells
(data not shown).
Localization of hABCB9 Protein to Lysosomes in Transfected
Cells--
The subcellular localization of hABCB9 protein was
determined by staining of intact permeabilized monolayers of
transfected cells (SKOV/ABCB9) and control cells (SKOV3) using
anti-ABCB9 antibody and FITC-conjugated secondary anti-rabbit IgG.
SKOV/ABCB9 cells exhibited strong granular perinuclear staining, which
was not evident in the control SKOV3 cells (Fig.
5A). The staining pattern
suggested a subcellular organelle location of ABCB9 in SKOV/ABCB9
cells. Further analysis was performed by double immunofluorescent staining using anti-ABCB9 antibody and a panel of organelle markers (Fig. 5, A and B). Anti-ABCB9-specific staining
showed a pattern different from those stained with markers of ER,
Golgi, and mitochondria (MitoTracker CMXRos, data not shown), but
overlapped with the lysosomal markers LAMP1 and LAMP2.
Anti-ABCB9-specific staining also overlapped partially with the
staining pattern of a marker of endosome (lysosomes and endosomes share
some common pathways in membrane trafficking). The colocalization of
hABCB9 with lysosomal marker LAMP1 was also observed in another
transfected clone in which hABCB9 is moderately expressed and in hABCB9
transiently transfected cells (data not shown).
To confirm the subcellular localization of hABCB9 protein, we performed
subcellular fractionation of SKOV/ABCB9 cells. Membrane proteins from
the postnuclear supernatant were separated by two step gradients into
the ER-mitochondria-rich fraction (Fraction IV) and Golgi-lysosome-rich
fraction (Faction V) (Fig.
6A). Western blot analysis
indicated that hABCB9 protein was enriched at the Golgi-lysosome
fraction. This Golgi-lysosome-rich fraction was further fractionated by
Percoll gradient to resolve lysosomal and Golgi membranes
(Fig. 6B). The profile of hABCB9 protein on this gradient
overlapped almost completely with that of the lysosomal marker. Thus,
the subcellular fraction analysis, in agreement with the
immunofluorescence study, indicates that hABCB9 protein is located in
the lysosome of SKOV/ABCB9 cells.
ABCB9 Protein in the Sertoli Cells of Mouse and Rat
Testes--
The high level of ABCB9 mRNA expression in human and
mouse testis prompted our further characterization of the expression of
ABCB9 protein in this tissue. For this analysis, ABCB9-specific polyclonal serum was preadsorbed with either GST or GST-ABCB9 fusion
protein to deplete GST-specific antibodies or both GST- and
ABCB9-specific antibodies, respectively. The depletion of ABCB9-specific antibodies was evaluated by immunostaining of SKOV/ABCB9 cells. As shown in Fig. 7A,
anti-GST-depleted serum displayed perinuclear punctate staining in
SKOV/ABCB9 cells; this specific staining was absent from the
anti-GST/ABCB9-depleted serum. Control SKOV3 cells were not stained by
either antiserum (data not shown). These adsorbed sera were designated
ABCB9-positive serum and -negative serum, respectively. These sera were
further examined by Western blot analysis of membrane proteins from
SKOV/ABCB9 cells and mouse and rat testis. Using the positive serum,
immunoreactive proteins were observed in mouse and rat testes, which
migrated similarly to that seen in the SKOV/ABCB9 cells. These
immunoreactive bands were not seen with the negative serum (data not
shown).
Immunohistochemistry was performed on frozen sections of adult mouse
and rat testes to determine the distribution of ABCB9 protein. Both
mouse and rat testis showed similar staining patterns when stained with
the positive serum, which were absent with negative serum (Fig. 7,
B and C). This ABCB9-specific stain was confirmed by using affinity-purified antiserum, which exhibited similar staining
patterns as shown in Fig. 7 (B and C).
Furthermore, this stain can be competed with the GST-ABCB9 protein but
not with GST (data not shown). The specific staining patterns seen with the positive serum indicates that ABCB9 protein is expressed in the
Sertoli cells of the seminiferous tubules.
The Sertoli cell is a tall (75-100 µm) columnar cell that spans the
seminiferous epithelium from the basement membrane to the luminal
region. Its lateral surfaces consist of slender processes, which
embrace differentiated sperm cells, the spermatocytes and spermatids.
Elongated spermatids are embedded in apical invaginations (crypts) of
Sertoli cells. The Sertoli cell can be seen to have a very elaborate
shape under the light microscope (Fig. 7D). The positive
staining demonstrated in Fig. 7 (B and C)
represents typical Sertoli cell staining.
We have isolated full-length cDNAs of ABCB9 and
examined its mRNA expression in selected tissues of human and
mouse. The greatest expression was observed in testis with moderate
levels in brain and spinal cord. We have localized hABCB9 to lysosomes
in transfected cells by two different approaches, immunofluorescent
double staining and subcellular fractionation. The cell line, SKOV3,
used for transfection has previously been shown to express other ABC
transporters localized to plasma membranes (24) or to mitochondrial
membranes (12). Therefore, lysosomes are not the default route for
transfected ABC proteins in SKOV3 cells. We conclude that lysosomes are
likely the natural location of ABCB9, even though it remains to be
elucidated what role it plays in that compartment.
Two classes of lysosomal and endosomal targeting signals,
YXX The expression of ABCB9 in Sertoli cells has allowed us to place its
lysosomal localization into a functional context. One of the Sertoli
cell's specialized functions is to phagocytose residual cytoplasmic
bodies, which detach from late spermatids during spermiation. In fact,
at the stage when fusion of lysosomes with the residual bodies occurs,
the lysosomal turnover rate increases sharply (33). The tight junctions
between Sertoli cells forms part of the blood-testis barrier separating
spermatogonia from spermatocytes and spermatids. Lysosomes may also be
critical for the detoxification of blood-borne compounds as part
of the barrier function of Sertoli cells (for a review, see Ref.
34). Further investigations will be required to determine the
subcellular localization of ABCB9 in Sertoli cells and to delineate its
functional significance.
Our findings have raised a number of fundamental questions. First, does
ABCB9 have a partner, or does it function as a homodimer? The TAP1 and
TAP2 heteromeric complex has been considered as a model for half ABC
transporters of other intracellular organelles. This model may be
especially apt in view of the close phylogenetic relationship between
ABCB9 and the TAP genes. Second, does ABCB9 play a general role in
lysosomes or is it involved in specialized lysosomes? Further
characterization of ABCB9 protein expression in Sertoli cells and
examination of ABCB9 protein in other tissues, such as the brain and
spinal cord, may shed light on this question. Finally, what is the
substrate of this transporter? Does it transport a single molecule or a
group of molecules? The answers to these questions will provide further
insight into the role of ABC proteins in lysosomes.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
cells transformed
with pGEX-1C and purified according to the method of Frangioni and Neel
(23). The fusion protein was injected into New Zealand White rabbits.
Immune serum was preadsorbed with fixed SKOV3 cells as described in
Childs et al. (24).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (46K):
[in a new window]
Fig. 1.
A, alignment of amino acid sequences of
hABCB9 (h), mABCB9 (m), and TAPL (r).
The amino acids identical among the three species are printed as
dash lines in sequences of mABCB9 and TAPL. Gaps in the
alignment are indicated by open squares. Sequences
corresponding to the conserved Walker A and B motifs and the ABC
signature sequence are indicated with black bars. The TM
segments predicted by TopPred II are boxed. The consensus
motifs for N-linked glycosylation are indicated with
stripped bars. The 43 amino acids that are absent from the
splice variant are marked by the line with filled
circles at each end. B, alignment of amino acid
sequences of hABCB9, TAP1, and TAP2. Only a portion of the alignment is
shown. Note that the 43-amino acid deletion in the hABCB9 splice
variant lines up in perfect position with exon 6 of both TAP1 and TAP2
(boxed sequences). The Walker A motif is
underlined.
Percentage of amino acid identity and similarity between the ABCB9
orthologs and the closest related proteins, TAPs (similarity/identity),
using the GAP program in GCG and standard parameter settings

View larger version (20K):
[in a new window]
Fig. 2.
Phylogenetic relationship of ABCB9 to other
ABC transporters. A neighbor-joining bootstrap tree is derived
from predicted amino acid sequences of representative ABC transporters
within the same subgroup. Sequences were aligned using ClustalX, and
the tree was generated from the alignment using PAUP*4.0. MDR1 protein
was split into the N-terminal half (n) and the C-terminal
half (c) in the analysis. The bootstrap values adjacent to
each branch indicate the percentage of times each group was recovered
in 500 replicates. (h, human; r, rat;
Sceri, Saccharomyces cerevisiae; Spo,
Schizosaccharomyces pombe).

View larger version (65K):
[in a new window]
Fig. 3.
A, Northern blots of
poly(A)+ RNA (2 µg) from various adult human normal
tissues (multiple tissue Northern blots, CLONTECH)
hybridized to the hABCB9 cDNA probe. B, Northern blots
of total RNA (20 µg) from various adult mouse tissues hybridized to
the mABCB9 cDNA probe and the control actin cDNA probe.
C, RT-PCR of total RNA from human brain and testis.
Different amounts (in microliters) of first strand cDNA used for
the RCR amplification are indicated. C1-s, C1-l:
PCR products using the same pair of primers as RT-PCR to amplify the
cDNA c1-s and c1-l, respectively.

View larger version (40K):
[in a new window]
Fig. 4.
Western blot analysis of ABCB9 protein from
SKOV/ABCB9 cells. A, 40-µg crude membrane
preparations (with exception of lane 2, 4 µg) from
SKOV/ABCB9 cells or control SKOV3 cell were subject to SDS-PAGE. The
transferred membranes were blotted with anti-ABCB9 antibodies that were
either untreated (none), preadsorbed with GST
(GST), or preadsorbed with GST/ABCB9 fusion protein
(GST/ABC). B, Western blot analysis using
anti-ABCB9 antibodies was performed on membrane preparations of
SKOV/ABCB9 cells that were treated with (+) or without (
)
N-glycosidase F (24). (Parallel experiments using
identically processed membrane fractions were examined for
deglycosylation of a known glycoprotein as positive control of the
enzymatic activity.)

View larger version (64K):
[in a new window]
Fig. 5.
A, immunofluorescence analysis of ABCB9
expression in SKOV/ABCB9 cells and control cells. SKOV3 or SKOV/ABCB9
cells were incubated with anti-ABCB9 antibodies and anti-LAMP1 mouse
monoclonal antibodies. B, double staining of hABCB9 and
various intracellular organelle marker in SKOV/ABCB9 cells. Cells were
stained with anti-ABCB9 antibodies and monoclonal antibodies against
one of the following proteins: lysosomal (lyso) protein
LAMP2 (H4B4), Golgi protein GPP130 (A1/118), ER protein Calnexin
(AF18), and endosomal (endo) protein transferrin receptor
(G1/122). The secondary antibodies were FITC-conjugated anti-rabbit IgG
and LRSC-conjugated anti-mouse IgG. Each pair of the horizontal
panels is an identical field of cells, visualized by fluorescence
microscopy with different filters.

View larger version (39K):
[in a new window]
Fig. 6.
Subcellular fractionation of SKOV/ABCB9
cells. A, equal quantities of proteins of the
postnuclear supernatant and membrane fractions obtained by two step
gradients were subjected to Western blot analysis. Organelle markers
indicate that mitochondria and ER were enriched in Fraction IV, and
lysosome and Golgi were enriched in Fraction V. B, Fraction
V from A was applied to a 18.8% Percoll gradient. Equal
volumes of each fraction from Percoll gradient fraction were then
subjected to Western blot analysis. Immunoblot analysis was performed
by using anti-ABCB9 antibodies and lysosomal marker anti-LAMP1, Golgi
marker anti-GPP130, ER marker anti-Calnexin, and mitochondria marker
anti-alcohol dehydrogenase (lyso, lysosome; mito,
mitochondria).

View larger version (106K):
[in a new window]
Fig. 7.
Immunohistochemical staining of ABCB9 in
mouse and rat testis. SKOV/ABCB9 cells (A) and mouse
(B) and rat (C) testis frozen sections were
stained with the positive or the negative serum. D,
schematic diagram of Sertoli cells. Bar, 10 µm.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(
is a bulky, uncharged, amino acid) and
di-leucine (or isoleucine) motifs (32), are typically found in the
short C-terminal cytoplasmic tails of a group of glycoproteins that
traverse the membrane once or twice. Both motif classes can be found in
the ABCB9 C terminus; however, it appears that they are also found in
many other ABC transporters not known to be localized to lysosomes or
endosomes. Therefore, whether these motifs serve as lysosomal targeting
signals for ABCB9 needs to be further clarified.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Jonathan A. Sheps for phylogenetic analysis; Dr. Wayne Vogl for photographing the tissue sections and giving helpful comments; Jefferson Loa for his assistance in immunohistochemical staining; and our colleagues, Douglas Hogue, Ping Lam, Renxue Wang, and Jonathan Sheps for helpful discussions and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants from the National Cancer Institute of Canada and the British Columbia Health Research Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF216494 and AF216495.
§ Present address: Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, K1A 0R6 Canada.
¶ Recipient of a Medical Research Council of Canada Studentship. Present address: Dept. of Zoology, University of British Columbia, Vancouver, British Columbia, V6T 1Z4 Canada.
** Recipient of a National Cancer Institute of Canada Steve Fonyo Fellowship. Present address: Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA 02129.
Recipient of a Canadian Breast Cancer Foundation Studentship.
§§ To whom correspondence should be addressed: Tel.: 604-877-6151; Fax: 604-877-6150; E-mail: vling@bccancer.bc.ca.
Published, JBC Papers in Press, March 23, 2000, DOI 10.1074/jbc.M001819200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ABC, ATP binding cassette; TM, transmembrane segment; NBD, nucleotide binding domain; ER, endoplasmic reticulum; RT-PCR reverse transcription-polymerase chain reaction, FITC, fluorescein isothiocyanate; LRSC, lissamine rhodamine; nt, nucleotide(s); bp, base pair(s); kb, kilobase(s); GST, glutathione S-transferase; PBS, phosphate-buffered saline; Mz, metrizamide; PAGE, polyacrylamide gel electrophoresis.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Higgins, C. F. (1992) Annu. Rev. Cell Biol. 8, 67-113 |
| 2. | Childs, S., and Ling, V. (1994) in Impartant Advances in Oncology (DeVita, V. T. , Hellman, S. , and Rosenberg, S. A., eds), Vol. 2 , pp. 21-36, J. B. Lippincott Company, Philadelphia, PA |
| 3. | Cole, S. P., and Deeley, R. G. (1998) Bioessays 20, 931-940 |
| 4. | Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L., Drumm, M. L., Iannuzzi, M. C., Collins, F. S., and Tsui, L.-C. (1989) Science 245, 1066-1073 |
| 5. | Townsend, A., and Trowsdale, J. (1993) Semin. Cell Biol. 4, 53-61 |
| 6. | Meyer, T. H., van Endert, P. M., Uebel, S., Ehring, B., and Tampe, R. (1994) FEBS Lett. 351, 443-447 |
| 7. | Kamijo, K., Taketani, S., Yokota, S., Osumi, T., and Hashimoto, T. (1990) J. Biol. Chem. 265, 4534-4540 |
| 8. | Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., Poustka, A. M., Mandel, J. L., and Aubourg, P. (1993) Nature 361, 726-730 |
| 9. | Holzinger, A., Kammerer, S., and Roscher, A. A. (1997) Biochem. Biophys. Res. Commun. 237, 152-157 |
| 10. | Holzinger, A., Kammerer, S., Berger, J., and Roscher, A. A. (1997) Biochem. Biophys. Res. Commun. 239, 261-264 |
| 11. | Gartner, J., Moser, H., and Valle, D. (1992) Nat. Genet. 1, 16-23 |
| 12. | Hogue, D. L., Liu, L., and Ling, V. (1999) J. Mol. Biol. 285, 379-389 |
| 13. | Csere, P., Lill, R., and Kispal, G. (1998) FEBS Lett. 441, 266-270 |
| 14. | Allikmets, R., Raskind, W. H., Hutchinson, A., Schueck, N. D., Dean, M., and Koeller, D. M. (1999) Hum. Mol. Genet. 8, 743-749 |
| 15. | Ortiz, D. F., Kreppel, L., Speiser, D. M., Scheel, G., McDonald, G., and Ow, D. W. (1992) EMBO J. 11, 3491-3499 |
| 16. | Cuervo, A. M., and Dice, J. F. (1998) J. Mol. Med. 76, 6-12 |
| 17. | Havelaar, A. C., de Gast, I. L., Snijders, S., Beerens, C. E., Mancini, G. M., and Verheijen, F. W. (1998) FEBS Lett. 436, 223-227 |
| 18. | Saint-Pol, A., Codogno, P., and Moore, S. E. H. (1999) J. Biol. Chem. 274, 13547-13555 |
| 19. | Yamaguchi, Y., Kasano, M., Terada, T., Sato, R., and Maeda, M. (1999) FEBS Lett. 457, 231-236 |
| 20. | Cloros, M., and von Heijne, G. (1994) Comput. Appl. Biosci. 10, 685-686 |
| 21. | Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., and Higgins, D. G. (1997) Nucleic Acids Res. 25, 4876-4882 |
| 22. | Swofford, D. L. (1999) PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4.0b2a , Sinauer Associates, Sunderland, MA |
| 23. | Frangioni, J. V., and Neel, B. G. (1993) Anal. Biochem. 210, 179-187 |
| 24. | Childs, S., Yeh, R. L., Hui, D., and Ling, V. (1998) Cancer Res. 58, 4160-4167 |
| 25. | Linstedt, A. D., Mehta, A., Suhan, J., Reggio, H., and Hauri, H. P. (1997) Mol. Biol. Cell 8, 1073-1087 |
| 26. | Storrie, B., and Madden, E. A. (1990) Methods Enzymol. 182, 203-225 |
| 27. | Altschul, S. F., Boguski, M. S., Gish, W., and Wootton, J. C. (1994) Nat. Genet. 6, 119-129 |
| 28. | Allikmets, R., Gerrard, B., Hutchinson, A., and Dean, M. (1996) Hum. Mol. Genet. 5, 1649-1655 |
| 29. | Greenberger, L. M. (1993) J. Biol. Chem. 268, 11417-11425 |
| 30. | Juranka, P., Zhang, F., Kulpa, J., Endicott, J., Blight, M., Holland, I. B., and Ling, V. (1992) J. Biol. Chem. 267, 3764-3770 |
| 31. | Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15665-15670 |
| 32. | Hunziker, W., and Geuze, H. J. (1996) Bioessays 18, 379-389 |
| 33. | Morales, C., Clermont, Y., and Nadler, N. J. (1986) Biol. Reprod. 34, 207-218 |
| 34. | Clermont, Y. (1993) in The Sertoli Cell (Russel, L. D. , and Griswold, M. D., eds) , p. xxi-xxv, Cache River Press, Clearwater, FL |
| 35. | Harlow, E., and Lane, D. (eds) (1988) Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
This article has been cited by other articles:
![]() |
C. Zhao, W. Haase, R. Tampe, and R. Abele Peptide Specificity and Lipid Activation of the Lysosomal Transport Complex ABCB9 (TAPL) J. Biol. Chem., June 20, 2008; 283(25): 17083 - 17091. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Abdul Jalil, V. Ritz, A. Jakimenko, C. Schmitz-Salue, H. Siebert, D. Awuah, A. Kotthaus, T. Kietzmann, C. Ziemann, and K. I. Hirsch-Ernst Vesicular localization of the rat ATP-binding cassette half-transporter rAbcb6 Am J Physiol Cell Physiol, February 1, 2008; 294(2): C579 - C590. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Demirel, Z. Waibler, U. Kalinke, F. Grunebach, S. Appel, P. Brossart, A. Hasilik, R. Tampe, and R. Abele Identification of a Lysosomal Peptide Transport System Induced during Dendritic Cell Development J. Biol. Chem., December 28, 2007; 282(52): 37836 - 37843. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Schroeder, S. Kremer, M. J. Kramer, E. Currie, E. Kwan, J. L. Watts, A. L. Lawrenson, and G. J. Hermann Function of the Caenorhabditis elegans ABC Transporter PGP-2 in the Biogenesis of a Lysosome-related Fat Storage Organelle Mol. Biol. Cell, March 1, 2007; 18(3): 995 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Schaheen, G. Patton, and H. Fares Suppression of the cup-5 mucolipidosis type IV-related lysosomal dysfunction by the inactivation of an ABC transporter in C. elegans Development, October 1, 2006; 133(19): 3939 - 3948. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sundaram, B. Echalier, W. Han, D. Hull, and L. Timmons ATP-binding Cassette Transporters Are Required for Efficient RNA Interference in Caenorhabditis elegans Mol. Biol. Cell, August 1, 2006; 17(8): 3678 - 3688. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Wolters, R. Abele, and R. Tampe Selective and ATP-dependent Translocation of Peptides by the Homodimeric ATP Binding Cassette Transporter TAP-like (ABCB9) J. Biol. Chem., June 24, 2005; 280(25): 23631 - 23636. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kubo, S. Sekiya, M. Ohigashi, C. Takenaka, K. Tamura, S. Nada, T. Nishi, A. Yamamoto, and A. Yamaguchi ABCA5 Resides in Lysosomes, and ABCA5 Knockout Mice Develop Lysosomal Disease-Like Symptoms Mol. Cell. Biol., May 15, 2005; 25(10): 4138 - 4149. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dani, A. Chaudhry, P. Mukherjee, D. Rajagopal, S. Bhatia, A. George, V. Bal, S. Rath, and S. Mayor The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment J. Cell Sci., August 15, 2004; 117(18): 4219 - 4230. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mutch, P. Anderle, M. Fiaux, R. Mansourian, K. Vidal, W. Wahli, G. Williamson, and M.-A. Roberts Regional variations in ABC transporter expression along the mouse intestinal tract Physiol Genomics, March 12, 2004; 17(1): 11 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rosenfeld, R. Vargas Jr., W. Xie, and R. M. Evans Genetic Profiling Defines the Xenobiotic Gene Network Controlled by the Nuclear Receptor Pregnane X Receptor Mol. Endocrinol., July 1, 2003; 17(7): 1268 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Santamarina-Fojo, A. T. Remaley, E. B. Neufeld, and H. B. Brewer Jr. Regulation and intracellular trafficking of the ABCA1 transporter J. Lipid Res., September 1, 2001; 42(9): 1339 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Vulevic,, Z. Chen, J. T. Boyd, W. Davis Jr., E. S. Walsh, M. G. Belinsky, and K. D. Tew Cloning and Characterization of Human Adenosine 5'-triphosphate-binding Cassette, Sub-family A, Transporter 2 (ABCA2) Cancer Res., April 1, 2001; 61(8): 3339 - 3347. [Abstract] [Full Text] |
||||
![]() |